Skin Surface Lipid-RNA Profile Obtained from Patients with Severe Asthma After Benralizumab Treatment
These findings suggest a suppression of both type 2 and non-type 2 inflammation in response to benralizumab treatment, with potential implications for asthma management. However, the limitations of the study include a small sample size and challenges in sebum collection, particularly among female participants. Although the noninvasive nature of this sampling method makes it attractive for both research and clinical applications, additional studies are needed to fully investigate the potential of SSL-RNA analysis as a noninvasive biomarker to assess treatment response in asthma.
Authors
- Yuuki Sandhu (ORCID: https://orcid.org/0009-0002-1388-3693)
- Tetsuya Kuwano (ORCID: https://orcid.org/0000-0001-8267-1868)
- Hitoshi Sasano
- Sonoko Harada (ORCID: https://orcid.org/0000-0002-3857-2624)
- Kyoko Shima (ORCID: https://orcid.org/0000-0002-9989-5400)
- Yuki Tanabe (ORCID: https://orcid.org/0000-0003-1463-2749)
- Norihiro Harada (ORCID: https://orcid.org/0000-0002-0962-5731)
- Yuya Uehara (ORCID: https://orcid.org/0000-0001-7329-4837)
- Takayoshi Inoue (ORCID: https://orcid.org/0000-0003-1038-4127)
- Kazuhisa Takahashi (ORCID: https://orcid.org/0000-0001-5749-4118)
- Shoko Ueda (ORCID: https://orcid.org/0000-0002-3263-1312)
- Sumiko Abe (ORCID: https://orcid.org/0000-0003-4746-0832)
- Ko Okumura
Institutions
- Kao Corporation (Japan) (JP)
- Juntendo University (JP)
Publication Details
- Journal
- Journal of Asthma and Allergy
- Published
- 2024-11-01
- DOI
- https://doi.org/10.2147/jaa.s490832
- Citations
- 2
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.65
Funders
- Kao Corporation
- Promotion and Mutual Aid Corporation for Private Schools of Japan
- Japan Society for the Promotion of Science